Review Article

Disorders of Potassium Homeostasis: Pathophysiology and

Management
Sumedh S Hoskote*, Shashank R Joshi**, Amit K Ghosh***

Abstract
Disorders of potassium homeostasis are common electrolyte abnormalities encountered in hospitalized patients.
Hypokalemia and hyperkalemia have been estimated to occur in about 21% and 3% of hospitalized patients,
respectively; though the morbidity and mortality associated with the latter is significantly higher. Potassium is a
predominantly intracellular ion and the understanding of its dynamics between intra- and extracellular fluid milieus,
along with its handling by the kidneys, is important in the diagnosis and treatment of potassium disorders. This
article aims to provide a clinically relevant update on management of potassium disorders for internists. ©

INTRODUCTION leading to death. The ECF acts as an intermediary between

P otassium is the main intracellular ion in the body
and its levels are crucial to normal homeostasis. It is mainly
contained within the intracellular fluid (ICF) compartment,
with only about 2% of the total body potassium residing
in the extracellular fluid (ECF).1 Nearly 80% of the cellular
stores are present in muscle, with erythrocytes, liver
and bone accounting for most of the remainder1 (Fig. 1).
The normal ratio between extracellular and intracellular
concentrations is important for maintenance of the resting
membrane potential and neuromuscular functioning.
Also, intracellularly, potassium participates in several vital
functions, such as cell growth, maintenance of cell volume,
DNA and protein synthesis, enzymatic function and acid-
base balance. Disorders of potassium balance are important
causes of ambulatory and in-hospital morbidity. In this
review, we will discuss the pathophysiology of potassium
transport, mechanisms and management of potassium
disorders commonly encountered in clinical practice.
the intracellular stores and the input/output mechanisms.
Potassium excretion matches the dietary intake, in the
absence of disease, and is executed predominantly by
the kidney, with about a 10% contribution from the large
intestine.
Potassium transfer between the extra- and intracellular
milieus is affected by a variety of other endogenous and
exogenous factors (Fig. 1). Cellular potassium uptake is
promoted by catecholamines and drugs activating β 2
adrenoceptors, and inhibited by α-antagonist drugs.
States of acidosis and alkalosis affect potassium because
it compensates for the movement of protons (hydrogen
ions). In acidosis, H+ ions move into cells and, to maintain
electrical balance, K+ ions move out into the ECF; and
vice-versa in alkalosis. A hyperosmolar ECF environment
can promote potassium efflux from the cells leading to
depletion of intracellular potassium (and, hence, total body

PATHOPHYSIOLOGY
Movement of Potassium Between ICF and ECF
Normal daily potassium intake is approximately 40-100
mEq, which is absorbed from the gut, enters the ECF and
is rapidly redistributed into the intracellular compartment
due to the action of post-prandial insulin. This is essential
because an additional 100 mEq of K+ in plasma would
increase plasma K+ concentration several fold, rapidly

Fig. 1 : Potassium homeostasis: Movement between intra- and

*Research Associate, Joshi Clinic, **Endocrinologist, Lilavati Hospital,
Bhatia Hospital and Joshi Clinic; Department of Endocrinology, Seth
GS Medical College and KEM Hospital; Mumbai. ***Associate Professor,
Mayo Clinic, Rochester, Minnesota.
extracellular fluids.
Movement of potassium between the body compartments is controlled
by various internal and external factors. Potassium predominantly
resides intracellularly, with only about 2% being present in the
extracellular fluid. RBCs, red blood cells. Data from Giebisch G.1

© JAPI  •  VOL. 56  •  SEPTEMBER 2008 www.japi.org 685

potassium). Finally, because potassium is predominantly
contained intracellularly, even if 1% of the cellular K+ content
were to be added to the ECF (due to lysis of cells, such as
rhabdomyolysis or hemolysis), it could result in severe
hyperkalemia.
Potassium Handling in the Nephron
Potassium handling by the nephron is unique, in that not
only is it reabsorbed but it is also secreted by the tubule; and
the amount excreted depends on the dietary intake.
Potassium is freely filtered at the glomerulus and
approximately 65% of the filtered load is reabsorbed in
the proximal convoluted tubule (PCT), which is tied to
the reabsorption of sodium and water. This takes place
isotonically and the K+ concentration of the fluid entering the
loop of Henle almost equals that of plasma. In the descending
part of the loop of Henle, the K+ concentration increases
(greater than that accounted for by the reabsorption of
water) owing to entry of K+ into the lumen, possibly driven
by the high K+ concentration of the medullary collecting
ducts.2 In the thick ascending part of the loop of Henle
(TALH), the Na+/K+/2Cl- cotransporter present on the luminal
border is responsible for reabsorption of potassium. This
is also the site of action of the loop diuretics, including
furosemide. The next segment, the distal convoluted tubule
(DCT), has been shown to be involved, to a small extent, in
secretion of K+ into the luminal fluid.3
The collecting duct (CD) is responsible for nearly all
the K+ secretion into the urine. The principal cells express
sodium and potassium ion channels on their luminal
surface. Since the electrochemical force for Na+ entry into
cells is much higher than that for K+, sodium reabsorption
predominates, thus creating a negative charge in the
lumen. This negative charge attracts K+ into the lumen and
also repels chloride, via the paracellular pathway, into the
peritubular capillaries. Aldosterone increases the activity of
the luminal Na+ channels, while also enhancing the function
of the basolateral Na+/K+/ATPase pump, thus amplifying the
entire process. Also, any factor increasing distal Na+ flow,
such as diuretic therapy or osmotic agents (e.g. mannitol,
high glucose in uncontrolled diabetes; which prevent
absorption of solutes due to increased tonicity of luminal
fluid) can lead to greater K+ secretion.
Finally, the acid-base status of the body and the
extracellular K+ affect each other via renal mechanisms. In
metabolic alkalosis, excess HCO3- is filtered, which leads
to increased distal HCO 3- delivery and bicarbonaturia.
Since HCO3- is a poorly reabsorbed anion, it makes the
luminal charge more negative and draws out K+ from the
collecting duct epithelium, leading to increased kaliuresis
and hypokalemia. Hypokalemia increases renal tubular
acid (ammonium ion) generation and, for each mole of
acid generated and excreted in urine, one mole of base
(HCO3-) is added to blood. Thus, it contributes towards the
metabolic alkalosis. In hyperkalemia, the converse occurs
and renal ammoniagenesis is impaired, leading to metabolic
acidosis.4
686 www.japi.org © JAPI  •  VOL. 56  •  SEPTEMBER 2008
Transtubular Potassium Gradient (TTKG)
The TTKG is a quick laboratory measure that gives
information about renal K+ secretory function.5 The aim is
to measure the K+ added into the tubular lumen as it passes
through the cortical collecting duct (CCD). Assuming that
the osmolality of the CCD luminal fluid is equal to that of
plasma, a simple ratio of CCD K+ concentration to the plasma
K+ concentration will yield the TTKG.
TTKG = [K+]CCD / [K+]Plasma
However, because it is clinically impractical to obtain
CCD fluid, the parameters are derived using urinary
measurements. TTKG is calculated as:
[K]Urine /OSM Urine [K]Urine OSMPlasma
TTKG = = X
[K]Plasma /OSM Plasma [K]Plasma OSMUrine
Normal TTKG is about 8-9, which may increase up to 11
if dietary potassium is increased. The TTKG is applied in the
appropriate clinical setting to estimate renal K+ secretion.6
In the setting of hypokalemia, a TTKG greater than 3 implies
renal K+ wastage, while in hyperkalemia, a TTKG lower than
7 implies impaired renal K+ secretion.6
HYPOKALEMIA
Hypokalemia is defined as a plasma K+ concentration
lower than 3.5 mEq/L. 7 It occurs in about 21% of all
hospitalized patients8 and goes undertreated in nearly a
fourth of all cases.9 Clinically, diuretic use is the commonest
cause of hypokalemia.10 Manifestations of hypokalemia
are consequences of the effects on the muscle resting
membrane potential (RMP) and on the acid-base status
(described above under “Pathophysiology”).
In muscles, low plasma K+ leads to a hyperpolarized
myocyte that tends to be more refractory to excitation. This
causes fatigue, myalgia and weakness, most pronounced in
the large proximal skeletal muscles, like those of the hip and
thigh. Worsening hypokalemia produces respiratory muscle
weakness and, eventually, generalized muscle paralysis,
including paralytic ileus.
In cardiac myocytes, potassium ion conductance is
directly related to the plasma K+ concentration.11 Hence,
hypokalemia reduces K + conductance and leads to a
prolonged repolarization phase of the cardiac action
potential, reflected in the electrocardiogram (ECG) as a
prolonged QT (or QU) interval. Other ECG changes include
flattening or inversion of the T wave, a prominent U-wave
(Fig. 2) and ST-segment depression. Patients receiving
digitalis treatment are prone to increased toxicity in the
setting of hypokalemia because digitalis and potassium
inhibit each other’s binding at the Na+/K+/ATPase pump.12
Causes
There are many disease processes that lead to or include
hypokalemia (Table 1). Broadly, hypokalemia can be
caused by a shift of K+ into the intracellular compartment,
increased loss from the gut or integument, or from
 Table 1 : Causes of hypokalemia
Redistribution to ICF
 Metabolic alkalosis
 Insulin
 Autonomic causes
 Stress, catecholamines
 β2-agonists, α-antagonists
Fig. 2 : Electrocardiogram (ECG) showing effects of hypokalemia.
 Anabolic states (Vitamin B12 or GM-CSF therapy)
The left panel shows a normal ECG (serum K+ = 4.4 mEq/L), while
 Hypokalemic periodic paralysis the right panel shows the ECG in hypokalemia (serum K+ = 3 mEq/L).
 Pseudohypokalemia Flattening of the T wave and a prominent U wave are seen in
Extra-renal Losses hypokalemia.
 Secretory diarrhea or laxative abuse
 Excessive sweating following exercise or ingestion of a carbohydrate-rich
 Intestinal neoplasms meal.15 Both these scenarios normally involve intracellular K+
 VIPoma uptake; but this process is abnormally increased in HypoKPP.
 Villous adenoma & McKittrick-Wheelock syndrome Serum K+ levels are low during the attack. HypoKPP warrants
Renal Losses
K+ replacement despite being a disorder of transcellular
 Primary mineralocorticoid excess
 Primary hyperaldosteronism (Conn syndrome) K+ shift. Thyrotoxic periodic paralysis (TPP) is a disorder
 Cushing syndrome characterized by elevated thyroxine, hypokalemia and
 CAH (CYP 11B1 or CYP 17) paralysis that most commonly occurs in patients of East and
 Glucocorticoid-remediable hyperaldosteronism Southeast Asian extraction.16 The importance of recognizing
 Hyperaldosteronism due to hyperreninemia this condition is that it is self-limited and administration of
 Chronic low circulating volume K+ supplementation can result in rebound hyperkalemia in
 Renin secreting tumor
nearly half the patients.16
 Renovascular and malignant hypertension
 Pseudohyperaldosteronism β2-agonists are potent promoters of cellular K+ uptake
 Liddle syndrome and, for this reason, they are important in the management
 11 β-HSD2 deficiency or antagonism (licorice, Cd++) of hyperkalemia. Recently, a bizarre cause of hypokalemia
 Increased distal Na+ delivery was reported in heroin abusers. Clenbuterol (a drug used
 Diuretics to treat airway obstruction in horses) was found to be an
 Bartter syndromes
adulterant in heroin, and led to hypokalemia, in addition
 Gitelman syndrome
 Increased distal delivery of non-reabsorbed anions to the autonomic effects (tachycardia, palpitations).17 This
 Renal tubular acidosis – Type 2 drug may also be abused by athletes for its propensity to
 Ketoacids (DKA), Penicillins increase lean muscle mass and reduce body fat.
 Bicarbonaturia from metabolic alkalosis Losses from the skin and gastrointestinal tract, if severe,
 Renal Tubular Acidosis – Type 1
can give rise to significant electrolyte depletion, resulting
Miscellaneous
 Reduced dietary intake (<40 mEq/day)
in hypokalemia. Infectious secretory diarrheas account for
 Barium toxicity, hypomagnesemia the vast majority of these. A pancreatic tumor secreting
 Hypothermia vasoactive intestinal polypeptide (VIPoma) is an exceedingly
rare entity, while a villous adenoma only infrequently
ICF, Intracellular fluid; GM-CSF, Granulocyte-Monocyte Colony
Stimulating Factor; VIPoma, tumor secreting Vasoactive Intestinal produces diarrhea sufficient to cause hypokalemia. Rectal
Polypeptide; CAH, Congenital Adrenal Hyperplasia; CYP 11B1, neoplasms (commonly villous adenomas) producing
11 β-hydroxylase; CYP 17, 17 α-hydroxylase; 11 β-HSD2, 11 electrolyte hypersecretion constitute the McKittrick-
β-hydroxysteroid dehydrogenase-2; DKA, Diabetic ketoacidosis
Wheelock syndrome.18
Diseases causing increased renal K+ loss can be grouped
intrinsic renal disease. Dynamics of K+ exchange between as: (1) those resulting from increased mineralocorticoid
ICF and ECF compartments have already been described effect, (2) those producing increased delivery of Na+ to
(Fig.1). To prevent a spuriously low serum K + reading the distal nephron segments, and (3) those producing
(pseudohypokalemia), blood samples should be maintained increased delivery of unabsorbed anions to the distal
at cool ambient temperatures13 and analyzed without much nephron segments. Some specific renal disorders have been
delay to prevent cellular uptake of K+. A similar phenomenon discussed in detail.
also occurs due to K+ uptake by the abnormal white cells Primary mineralocorticoid excess can result from
in myeloproliferative disorders.14 Several unique causes of primary hyperaldosteronism i.e., Conn syndrome (increased
hypokalemia need special mention. production of aldosterone from a benign or malignant adrenal
Hypokalemic periodic paralysis (HypoKPP) is an neoplasm), or from generalized adrenal hyperfunction
autosomal-dominant inherited disorder involving mutations (Cushing syndrome). Increased mineralocorticoid action
of ion channels present on the muscle sarcolemma. Attacks can occur due to mineralocorticoids produced in congenital
of paralysis occur, beginning in adolescence, after rest adrenal hyperplasia. Inborn deficiencies of the 11

© JAPI  •  VOL. 56  •  SEPTEMBER 2008 www.japi.org 687

β-hydroxylase (CYP 11B1) and 17 α-hydroxylase (CYP 17)
enzymes lead to increased levels of 11-deoxycorticosterone.
Genetically male children with CYP 17 deficiency manifest
as pseudohermaphroditism (female genitalia), while
females present in later life with primary amenorrhea. Both
deficiencies have adult-onset forms as well.
Liddle syndrome is a rare autosomal dominant genetic
disorder manifested by a gain-of-function of the epithelial
sodium channel (ENaC) of the principal cell in the
collecting duct.19 Excessive Na+ is reabsorbed and, as a
direct consequence, excessive K+ is secreted – leading to
hypokalemia. Patients are volume overloaded, leading
to hypertension in the setting of a suppressed renin-
angiotensin-aldosterone (RAA) axis. A loss-of-function
mutation of the ENaC produces aldosterone resistance, a
syndrome exactly the opposite of Liddle syndrome, which
is discussed later.
Another condition producing a similar picture to
that of Liddle syndrome is the syndrome of apparent
mineralocorticoid excess. Cortisol secreted by the
adrenals possesses some mineralocorticoid action but, in
aldosterone target tissues, the enzyme 11 β-hydroxysteroid
dehydrogenase-2 (11-βHSD2) converts cortisol to a
non-mineralocorticoid, cortisone. 20 Symptoms of
hyperaldosteronism develop if the activity of this enzyme
is lacking, or in the presence of inhibitors (licorice 21 or
cadmium from tobacco smoke22).
Glucocorticoid-remediable hyperaldosteronism is a
genetic condition wherein the gene for 11 β-hydroxylase
(the enzyme upregulated by corticotropin to synthesize
cortisol) contains the correct promoter but carries the
bases for aldosterone synthase in its coding region (chimeric
gene duplication).23 Hence, aldosterone synthesis occurs
in the region of the adrenal (zona fasciculata) responsible
for cortisol secretion. Administration of dexamethasone
can diagnose as well as manage this condition, because
suppression of corticotropin takes away the stimulus for
excessive aldosterone synthesis.
Bartter syndrome is a group of genetic conditions
resulting from defective reabsorption of sodium from the
TALH due to a variety of dysfunctional ion-transport proteins.
These include the Na+/K+/2Cl- cotransporter (Bartter I),24 the
apical (luminal) potassium channel (Bartter II)25 and two
defects in the basolateral chloride channel responsible for
potasium-chloride flux through the tubular cell (Bartter III
& IV).26 Recently, a milder variant of Bartter syndrome with
hypocalcemia has also been described (Bartter V). 27 All
the Bartter syndrome genetic defects are inherited in an
autosomal recessive fashion, except for Bartter syndrome
V, which follows autosomal dominant inheritance.
Reabsorption of Na + is impaired and the resultant
excessive natriuresis has two important implications – there
is increased distal Na+ flow and the volume depletion causes
activation of the RAA axis. Both factors are responsible
for the excessive K+ excretion, leading to hypokalemia.
In the TALH, K+ absorption is reduced and, consequently,
688 www.japi.org © JAPI  •  VOL. 56  •  SEPTEMBER 2008
its backflow into the lumen is also reduced. Since it is
this luminal positive charge that drives transcellular
reabsorption of other cations like Ca++ and Mg++, Bartter
syndrome is associated with hypocalcemia (hypercalciuria)
and hypomagnesemia. This fact is utilized in differentiating
Bartter syndrome from Gitelman syndrome, of which
hypocalciuria is a hallmark.28
Gitelman syndrome is an autosomal recessive genetic
defect resulting in dysfunction of Na + absorption by
the thiazide-sensitive Na + /Cl - cotransporter (NCCT )
located in the DCT.29 It is characterized by hypokalemia,
metabolic alkalosis, hypomagnesemia, and hypocalciuria.30
Hypomagnesemia is considered the hallmark of NCCT
dysfunction31 and is thought to occur due to reduced
activity of epithelial Mg++ receptors,32 while hypocalciuria
occurs due to increased proximal tubular reabsorption of
Ca++.32
Renal tubular acidosis (RTA) is an umbrella term for
the common presentation of hyperchloremic metabolic
acidosis with a normal anion gap, caused by a renal tubular
dysfunction. There are four types of RTA and all, except type
4, produce hypokalemia.
RTA Type 1, also known as distal RTA, is caused by an
impairment in acidification of urine due to dysfunctional
acid secretion in the collecting ducts. There is also an
associated defect of K+ conservation, the mechanism of
which is uncertain. The urinary excretion of ammonium
(NH4+) is disproportionately low compared to the blood
pH, which produces the characteristic finding of urine pH
greater than 5.5 even in the setting of acidosis,33 aiding
in the differentiation from RTA Type 2. Chronic acidosis is
responsible for the renal calculi formed in Type 1 RTA by
two synergistic mechanisms. Acidosis reduces calcium
reabsorption, increasing the Ca++ concentration in tubular
fluid, while simultaneously enhancing citrate reabsorption,
reducing its concentration.34 Usually, calcium binds citrate
to form a soluble compound but, due to the imbalance in
this ratio, calcium binds phosphate to produce a 50-times
less soluble compound that precipitates in the alkaline urine
to produce renal calculi.
RTA Type 2, also known as proximal RTA, can occur as a
primary condition, with or without features of generalized
proximal tubular dysfunction (Fanconi syndrome), or
secondary to drugs such as carbonic anhydrase (CA)
inhibitors. The result is impaired proximal reabsorption
of HCO3-. Distal sites in the nephron receive more than
the usual HCO3- load and, since they are not as adept at
its reabsorption, the HCO3- is lost. Bicarbonaturia is the
characteristic of this condition. Eventually, the plasma
HCO3- drops to a lower level, at which a new equilibrium
is established and HCO 3 - is no longer lost in urine.
Bicarbonate replacement therapy is difficult because a
fractional HCO3- excretion of more than 15% is observed
and HCO3- may be lost before the desired pH normalization
is achieved.35 Interestingly, the defect in proximal tubular
function protects these patients from renal calculi and
nephrocalcinosis because of the normal/increased citrate
in the tubular fluid. In RTA Type 2, relative to Type 1, a large
quantity of HCO3- needs to be replaced (5-15 mmol/kg/day
vs. 1-2 mmol/kg/day). Since alkali replacement itself causes
hypokalemia, the K+ replacement required in RTA Type 2 is
greater than that required in RTA Type 1.
RTA Type 3 is a rare condition caused by a mutation of
the intracellular form of CA (CA-II).36 The deficiency of a
functional CA-II enzyme gives rise to impaired proximal
HCO3- reabsorption as well as impaired distal acid secretion
i.e. features of both RTA types 1 and 2. Other associated
features are osteoporosis, cerebral calcifications and mental
retardation.
Diagnosis
Hypokalemia should be suspected in any patient
presenting with generalized or proximal muscle weakness
or cardiac arrhythmias. History of gastrointestinal losses,
use of any medications (especially diuretics), renal disease
and history of familial conditions should be actively sought.
Conditions leading to transcellular K+ shift can be excluded
with a good history and physical examination. Laboratory
values for serum and urinary electrolytes, along with the
blood pressure and plasma renin activity (PRA), are the main
tools in narrowing down the causes of hypokalemia.
The headings listed in Table 1 (see “Renal losses”) each
represent a pathophysiologic mechanism in the process
causing hypokalemia and each is a distinct endpoint in the
diagnostic pathway (Fig. 3).
Once transcellular shift has been excluded, the first
step is to find out if K+ has been lost via renal or extra-
renal mechanisms. A daily urinary K+ excretion of > 20
mEq suggests renal K+ wastage. If a renal cause has been
found, the next factor to ascertain is the aldosterone
status, since that is the main stimulus for K+ loss. One of
the reliable clinical manifestations of hyperaldosteronism
is hypertension and, hence, the blood pressure (BP) guides
the further diagnostic course. If the BP is low or normal, we
can eliminate aldosterone as the cause for hypokalemia.
The other reasons for increased K+ loss are increased distal
delivery of Na+ or HCO3-. These causes are looked for using
serum HCO3- and urinary chloride. Increased distal Na+ flow
is the result of impaired Na+ reabsorption due to an inherited
defect of the transporters (Bartter and Gitelman syndromes)
or due to their blockade by diuretics. These disorders
secondarily cause metabolic alkalosis, producing elevated
serum HCO3-. Because Cl- is simultaneously reabsorbed with
Na+, the above conditions lead to Cl- loss as well, causing a
high daily Cl- excretion. On the other hand, an extra-renal
cause of metabolic alkalosis (like vomiting or nasogastric
suction) leads to increased serum HCO3- with a resultant
increased tubular HCO3-, whose negative charge repels
chloride. The Cl- is driven out of the tubular lumen, leading
to low urinary Cl- excretion. In case the serum HCO3- is low,
renal tubular acidosis is diagnosed.
Elevated BP implies excess mineralocorticoid action;
however, this may be due to or independent of renin levels.
© JAPI  •  VOL. 56  •  SEPTEMBER 2008 www.japi.org 689
Fig. 3 : Algorithm for diagnosis of hypokalemia.
UK, urinary potassium; GI, gastrointestinal; BP, blood pressure; Aldo,
aldosterone; CAH, congenital adrenal hyperplasia; HTN, hypertension;
UCl, urinary chloride; RTA, renal tubular acidosis.
Hence, plasma renin activity should be tested prior to
aldosterone. Conditions like Liddle syndrome give a clinical
picture of hyperaldosteronism despite a suppressed RAA
axis because their pathophysiology mimics aldosterone
excess at the level of the target tissues.
Treatment
Hypokalemia caused due to true potassium deficit
should be treated with K+ replacement, though if serious
complications are expected, hypokalemia resulting from
transcellular shifts may also be treated similarly.37 Potassium
chloride or acetate are used depending on coexistent
alkalosis or acidosis, respectively.38 Other modalities can be
employed depending on the specific underlying pathologic
condition. If acidosis and hypokalemia coexist, the
hypokalemia must be treated before the acidosis because
alkali administration can further aggravate hypokalemia.
The 2005 American Heart Association (AHA) guidelines
recommend K+ replacement for serum levels below 2.5
mEq/L to avert risk of cardiac arrhythmias.39 Replacement
should be carried out gradually, rather than rapidly, unless
the patient’s severity so demands. It is difficult to estimate
the K+ requirement because the ECF concentration does
not reflect body stores. Hence, it is important to frequently
monitor serum K+ while administering therapy. Response to
treatment improves with co-administration of magnesium
replacement, especially in hypokalemia that is refractory
to therapy. Care must be taken to avoid overcorrection
of the deficit, because rebound hyperkalemia is a serious
complication of therapy.
Some authors recommend that replacement should be
initiated with oral potassium chloride because a greater
rise in ECF potassium can be achieved with this route
at the expense of fewer adverse events and parenteral
administration should be reserved for patients unable to
take enteral doses.40 According to the AHA guidelines,39
K + replacement should be empiric, with a maximum
intravenous potassium chloride infusion rate of 10-20
mEq/L, while continuously monitoring the ECG. If K+ is
infused via a central line, it should be ensured that the tip
of the catheter is not in the right atrium. If cardiac arrest is
imminent, a rapid dose of 10 mEq over 5 minutes is required
and may be repeated once. The therapeutic requirement
for such a rapid infusion must be recorded on the patient’s
chart.
HYPERKALEMIA
Hyperkalemia is defined as a plasma K+ concentration
greater than 5 mEq/L. It occurs in about 3.3% of all
hospitalized patients,41 most commonly in patients of
chronic renal insufficiency,39 and can carry a high rate
of mortality.41 As for hypokalemia, the manifestations of
hyperkalemia also relate to neuromuscular and acid-base
effects. Increased ECF K+ concentration forces K+ into the
cells through the always-open leaky potassium channels,
leading to a slight depolarization. A constant state of
depolarization affects excitability and, once again, the
effect is fatigue and weakness. If severe, respiratory muscle
weakness can be a life-threatening complication.
In cardiac myocytes, hyperkalemia causes increased
K+ conductance.11 Since the K+ current is responsible for
repolarization, the first manifestation of hyperkalemia is
a rapid repolarization, reflected on the ECG as a sharp,
peaked T wave. Increased K+ conductance also makes the
RMP more negative, to a level at which Na+ channels start
getting inactivated.42 Hyperkalemia can also induce an
atrioventricular nodal block,43 reflected as a prolonged
PR interval and a ventricular rhythm with wide QRS
complexes.42 P wave amplitude decreases, and may not
be detectable, due to an ‘electrical paralysis’ of the atria.44
With increasing severity of hyperkalemia, the widened QRS
tends to merge with the peaked T wave (Fig. 4), producing
a characteristic sine wave pattern.45 Eventually, the cardiac
arrhythmia deteriorates into ventricular fibrillation or
asystole, leading to death.
Causes
The various causes of hyperkalemia fall into two main
pathophysiologic groups – movement of K+ from the ICF
to the ECF and impaired renal excretion (Table 2). Factors
causing transcellular shift of K+ have already been discussed
(Fig. 1). Renal causes can, again, be either related to a
defective mineralocorticoid action or due to an intrinsic
tubular inability to secrete potassium. Oliguric renal failure
can, by virtue of reduced renal perfusion and glomerular
filtration rate (GFR), cause reduced K+ secretion. Additionally,
the initiating pathologic process may entail catabolism
and metabolic acidosis, both of which would increase
serum K+. Thus, two separate mechanisms are responsible
for hyperkalemia in oliguric renal failure. This may be
compensated by RAA axis activation, but decompensation
occurs if GFR falls below a critical value of about 10 mL/
min.
690 www.japi.org © JAPI  •  VOL. 56  •  SEPTEMBER 2008
Primary aldosterone deficiency can result from either
a generalized adrenal cortex failure (Addison’s disease) or
from an inborn enzyme defect such as the 21-hydroxylase
(CYP 21A2) deficiency. The CYP 21A2 deficiency, which
may present in childhood or adulthood, causes congenital
adrenal hyperplasia and presents with virilization and
hypotension. Hyporeninemic hypoaldosteronism is a
condition commonly seen in association with diabetic
nephropathy and usually occurs in the presence of some
underlying renal pathology causing volume expansion.46
The volume expansion secondarily causes suppression of
the RAA axis, eventually manifesting as hyperkalemia.
Many drugs interact with the RAA axis. Non-steroidal
anti-inflammatory drugs (NSAIDs) cause hyporeninemia by
impairing prostaglandin synthesis in the juxtaglomerular
apparatus, which are essential for renin release. Additionally,
hypoaldosteronism can be caused by fluoride toxicity and
heparin, which act as inhibitors of aldosterone synthesis,
or by the angiotensin-converting enzyme inhibitors
(ACEI) or angiotensin-receptor blockers, which antagonize
angiotensin, the main stimulus for aldosterone release from
the adrenals.
Impaired K + secretion can result from receptor-
antagonism of aldosterone (spironolactone) or from
blockade of the principal cell Na+ channel (ENaC) by drugs
like amiloride, triamterene, amantadine and trimethoprim.
RTA Type 4, also known as hyperkalemic distal RTA, is
usually the consequence of some other underlying renal
pathology. There is reduced secretion of K +, leading to
chronic hyperkalemia. And, as discussed earlier (see
“Pathophysiology”), hyperkalemia impairs NH4+ production
in the collecting duct, leading to defective generation of
acid for excretion, and metabolic acidosis. Type 4 RTA should
be taken as a descriptive term rather than as a discreet
pathology, because any condition in which the RAA axis
is interrupted can potentially produce Type 4 RTA. Lastly,
pseudohypoaldosteronism is a rare familial condition in
which there is a defective gene coding for the ENaC.47 This
Fig. 4 : Electrocardiogram (ECG) of a patient with severe hyperkalemia.
The ECG shows a wide QRS complex merging with the peaked T wave,
producing a sine-wave pattern. Right axis deviation (I, aVF) can also be
appreciated.
 Table 2 : Causes of hyperkalemia
Redistribution to ECF
 Metabolic acidosis
 Massive cell rupture
 Rhabdomyolysis, burns, hemolysis
 Tumor lysis syndrome
 Hyperosmolarity (e.g. severe hyperglycemia)
 Insulin resistance or deficiency
 Drugs
 β-blocker therapy
 Digitalis
 Succinylcholine
 Hyperkalemic periodic paralysis
Impaired Renal Excretion
Fig. 5 : Algorithm for approach to hyperkalemia.
 Oliguric renal failure DKA, diabetic ketoacidosis; GFR, glomerular filtration rate; ACEI,
 Primary mineralocorticoid deficiency angiotensin-converting enzyme inhibitors; NSAIDs, nonsteroidal anti-
 Addison’s disease inflammatory drugs; CSA, cyclosporine.
 Congenital adrenal hyperplasia (CYP 21A2) * low aldosterone
 Secondary mineralocorticoid deficiency
 Hyporeninemic hypoaldosteronism should be used. For moderate hyperkalemia (6-7 mEq/L),
 NSAIDs an intracellular shift of K+ should be achieved using an
 ACE Inhibitors or ARBs insulin-glucose drip, sodium bicarbonate and salbutamol.
 Heparin and fluoride In severe hyperkalemia (>7 mEq/L with toxic ECG changes),
 Impaired K+ secretion the cardiac toxicity needs to be controlled at the earliest to
 Renal tubular acidosis – Type 4 prevent the advent of fatal arrhythmias. Calcium chloride (or
 Potassium-sparing diuretics
gluconate) can be used as an infusion to achieve membrane
 Amantadine, trimethoprim
 Aldosterone resistance
stabilization. In addition to calcium, all the modalities
(pseudohypoaldosteronism) mentioned above should be employed to lower serum K+
Miscellaneous levels. In refractory cases, hemodialysis may be used as a
 Pseudohyperkalemia last resort of treatment.
 Exercise-induced hyperkalemia (self-limiting)
In summary, disorders of potassium metabolism
ECF, Extracellular fluid; CYP 21A2, 21-hydroxylase; ACE, Angiotensin are commonly encountered in clinical practice. Taking
converting enzyme; ARBs, Angiotensin receptor blockers; NSAIDs, Non-
an excellent clinical history, along with a thorough
steroidal antiinflammatory drugs
understanding of potassium pathophysiology, will help
loss-of-function mutation produces aldosterone resistance the clinician to make an accurate diagnosis and initiate
and, in spite of elevated aldosterone levels, the kidneys appropriate treatment. Additionally, anticipating potassium
continue to lose Na+ and retain K+. disorders in patients receiving medications like diuretics
(hypokalemia) or ACEI (hyperkalemia), especially in patient
Diagnosis
with co-morbid illness and chronic kidney disease, will help
The initial presentation of hyperkalemia can be in ensuring patient safety and optimizing patient care.
paralysis, cardiac arrhythmias or ileus. 48 History of
diabetes, medications and any familial disorders should REFERENCES
be sought. Laboratory values of serum electrolytes, 1. Giebisch G. Renal potassium transport: mechanisms and regulation.
osmolality, blood urea nitrogen (BUN) and creatinine, Am J Physiol Renal Physiol 1998;274:F817-33.
along with urine electrolytes should be obtained. The 2. Jamison RL, Lacy FB, Pennell JP, Sanjana VM. Potassium secretion by
diagnostic approach to hyperkalemia is detailed in the descending limb or pars recta of the juxtamedullary nephron in
vivo. Kidney Int 1976;9:323-32.
Fig. 5.
3. Velázquez H, Ellison DH, Wright FS. Chloride-dependent potassium
Treatment secretion in early and late renal distal tubules. Am J Physiol Renal
Treatment of hyperkalemia involves three major steps: Physiol 1987;253:F555-62
(1) to reverse the cardiac effects, (2) to promote intracellular 4. DuBose TD Jr, Good DW. Chronic hyperkalemia impairs ammonium
transport and accumulation in the inner medulla of the rat. J Clin
uptake, and (3) to remove excess potassium from the body. Invest 1992;90:1443-49.
Later, on subsidence of the acute event, patients need to 5. West ML, Marsden PA, Richardson RM, Zettle RM, Halperin ML. New
be put on a maintenance regimen to prevent episodes of clinical approach to evaluate disorders of potassium excretion. Miner
hyperkalemia. Various treatment modalities and dosages Electrolyte Metab 1986;12:234-8.
are summarized in Table 3.39,48,49 6. Ethier JH, Kamel KS, Magner PO, Lemann J Jr, Halperin ML. The
transtubular potassium concentration in patients with hypokalemia
According to the 2005 AHA guidelines,39 management and hyperkalemia. Am J Kidney Dis 1990;15:309-15.
should be guided by the serum K+ level. In mild hyperkalemia
7. Gennari FJ. Hypokalemia. N Engl J Med 1998;339:451-58.
(5-6 mEq/L), furosemide and sodium polystyrene sulfonate
8. Paice BJ, Paterson KR, Onyanga-Omara F, Donnelly T, Gray JM, Lawson

© JAPI  •  VOL. 56  •  SEPTEMBER 2008 www.japi.org 691

 Table 3 : Treatment of hyperkalemia
Therapeutic target Dose and route Onset Duration Comments
and medications of action
Membrane effects
 Calcium chloride 5-10 mL of 10% solution Immediate 30 min. Can worsen digitalis toxicity. Monitor
   or gluconate IV over 2-5 min. ECG, stop if bradycardia develops.
Intracellular shift of K+
 Insulin-glucose drip 10 Units Regular insulin IV 15-30 min. 2-6 h. Glucose unnecessary if
with 50 mL of 50% glucose blood sugar > 250 mg/dl
 Salbutamol 2-4 ml of 5 mg/ml salbutamol 15-30 min. 2-3 h. Synergistic with insulin. May cause
by neubulizer over 15 min. a brief rise in plasma K+.
 Sodium bicarbonate 50 mEq IV over 5 min. 15-30 min. 1-2 h. Should be used along with insulin
and salbutamol; may be less
effective in ESRD
Removal of excess K+
 Furosemide 40-80 mg furosemide IV, with 15-60 min. 4 h. Causes kaliuresis. Only effective if
saline if coexistent adequate renal response to loop diuretics.
valume depletion
 Sodium polystyrene 15-30 g in 50-100 mL of 20% 1-2 h. 4-6 h. Sorbitol may be associated with bowel
   sulfonate sorbitol, either orally or as a necrosis. May lead to Na+ retention.
retention enema Rectal route acts faster.
 Hemodialysis 15-30 min. Avoid ultrafiltration in the first hour
of dialysis
Long-term maintenance therapy
 Restriction of K+ intake to < 2-3 g/day
 Discontinuation of drugs interfering with K+ homeostasis
 Enhanced K+ excretion: furosemide, thiazides
 Fludrocortisone (in hypoaldosteronism)
 Long-term sodium polystyrene sulfonate therapy
IV, Intravenously; ESRD, End-stage renal disease. Data from: Hollander-Rodriguez JC et al. (48), American Heart Association 2005 Guidelines (39) and
Gennari FJ (49).

DH. Record linkage study of hypokalaemia in hospitalized patients.
Postgrad Med J 1986;62:187-91.
9. Paltiel O, Salakhov E, Ronen I, Berg D, Israeli A. Management of severe
hypokalemia in hospitalized patients: a study of quality of care based
on computerized databases. Arch Intern Med 2001;161:1089-95.
10. Knochel JP. Diuretic-induced hypokalemia. Am J Med 1984;77:18-
27.
11. Sakmann B, Trube G. Conductance properties of single inwardly
rectifying potassium channels in ventricular cells from guinea-pig
heart. J Physiol 1984;347:641-57.
12. Middleton DA, Rankin S, Esmann M, Watts A. Structural insights into
the binding of cardiac glycosides to the digitalis receptor revealed
by solid-state NMR. Proc Natl Acad Sci U S A 2000;97:13602-07.
13. Masters PW, Lawson N, Marenah CB, Maile LJ. High ambient
temperature: a spurious cause of hypokalaemia. BMJ 1996;312:1652-
53.
14. Naparstek Y, Gutman A. Case report: spurious hypokalemia
in myeloproliferative disorders. Am J Med Sci 1984;288:
175-7.
15. Levitt JO. Practical aspects in the management of hypokalemic
periodic paralysis. J Transl Med 2008;6:18.
16. Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features
of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med
1999;159:601-06.
17. Centers for Disease Control and Prevention (CDC). Atypical reactions
associated with heroin use—five states, January-April 2005. MMWR
Morb Mortal Wkly Rep 2005;54:793-96.
18. Popescu A, Orban-Schiopu AM, Becheanu G, Diculescu M. McKittrick-
Wheelock syndrome - a rare cause of acute renal failure. Rom J
Gastroenterol 2005;14:63-66.
19. Warnock DG. Liddle syndrome: genetics and mechanisms of Na+
channel defects. Am J Med Sci 2001;322:302-07.
20. Hammer F, Stewart PM. Cortisol metabolism in hypertension. Best
Pract Res Clin Endocrinol Metab 2006;20:337-53.
21. van Uum SH, Lenders JW, Hermus AR. Cortisol, 11beta-hydroxysteroid
dehydrogenases, and hypertension. Semin Vasc Med 2004;4:121-
28.
22. Yang K, Julan L, Rubio F, Sharma A, Guan H. Cadmium reduces 11
beta-hydroxysteroid dehydrogenase type 2 activity and expression
in human placental trophoblast cells. Am J Physiol Endocrinol Metab
2006;290:E135-42.
23. McMahon GT, Dluhy RG. Glucocorticoid-remediable aldosteronism.
Arq Bras Endocrinol Metabol 2004;48:682-86.
24. Simon DB, Karet FE, Hamdan JM, DiPietro A, Sanjad SA, Lifton RP.
Bartter’s syndrome, hypokalaemic alkalosis with hypercalciuria, is
caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet
1996;13:183-88.
25. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A,
Trachtman H, et al. Genetic heterogeneity of Bartter’s syndrome
revealed by mutations in the K+ channel, ROMK. Nat Genet
1996;14:152-56.
26. Simon DB, Bindra RS, Mansfield TA, Nelson-Williams C, Mendonca E,
Stone R, et al. Mutations in the chloride channel gene, CLCNKB, cause
Bartter’s syndrome type III. Nat Genet 1997;17:171-78.
27. Vezzoli G, Arcidiacono T, Paloschi V, Terranegra A, Biasion R, Weber
G, et al. Autosomal dominant hypocalcemia with mild type 5 Bartter
syndrome. J Nephrol 2006;19:525-28.
28. Bettinelli A, Bianchetti MG, Girardin E, Caringella A, Cecconi M, Appiani
AC, et al. Use of calcium excretion values to distinguish two forms of
primary renal tubular hypokalemic alkalosis: Bartter and Gitelman
syndromes. J Pediatr 1992;120:38-43.
29. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM,
et al. Gitelman’s variant of Bartter’s syndrome, inherited hypokalaemic
alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl
cotransporter. Nat Genet 1996;12:24-30.

692 www.japi.org © JAPI  •  VOL. 56  •  SEPTEMBER 2008

30. Gitelman HI, Graham JB, Welt LG. A new familial disorder characterized Physician 2006;73:283-90.
by hypokalemia and hypomagnesemia. Trans Assoc Am Phys 49. G e n n a r i FJ . D i s o r d e r s o f p o t a s s i u m h o m e o s t a s i s .
1966;79:221-23. Hypokalemia and hyperkalemia. Crit Care Clin 2002;18:
31. Fukuyama S, Hiramatsu M, Akagi M, Higa M, Ohta T. Novel mutations 273-88.
of the chloride channel Kb gene in two Japanese patients clinically
diagnosed as Bartter syndrome with hypocalciuria. J Clin Endocrinol
Metab 2004;89:5847-50.
32. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG,
Bindels RJ. Enhanced passive Ca2+ reabsorption and reduced Mg2+
channel abundance explains thiazide-induced hypocalciuria and
hypomagnesemia. J Clin Invest 2005;115:1651-58.
33. Halperin ML, Richarson RMA, Bear RA, Magner PO, Kamel K, Ethier
J. Urine ammonium: the key to the diagnosis of distal renal tubular
acidosis. Nephron 1988;50:1-4.
34. Buckalew VM Jr. Nephrolithiasis in renal tubular acidosis. J Urol
1989;141(3 Pt 2):731-37.
35. Ring T, Frische S, Nielsen S. Clinical review: Renal tubular
acidosis—a physicochemical approach. Crit Care 2005;9:
573-80.
36. Shah GN, Bonapace G, Hu PY, Strisciuglio P, Sly WS. Carbonic
anhydrase II deficiency syndrome (osteopetrosis with renal tubular
acidosis and brain calcification): novel mutations in CA2 identified by
direct sequencing expand the opportunity for genotype-phenotype
correlation. Hum Mutat 2004;24:272.
37. Kim HJ, Han SW. Therapeutic approach to hyperkalemia. Nephron
2002;92(suppl 1):33-40.
38. Glover P. Hypokalaemia. Crit Care Resusc 1999;1:239-51.
39. 2005 American Heart Association Guidelines for Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care. Part 10.1: Life-
Threatening Electrolyte Abnormalities. Circulation 2005;112:IV-121-
IV-125.
40. Mount DB, Zandi-Nejad K. Disorders of Potassium Balance. In: Brenner
BM, Rector FC, Livine SA, editors: The Kidney. 7th ed. Philadelphia: WB
Saunders; 2002. p. 1015.
41. Stevens MS, Dunlay RW. Hyperkalemia in hospitalized patients. Int
Urol Nephrol 2000;32:177-80.
42. Mirvis DM, Goldberger AL. Electrocardiography. In: Braunwald E,
Zipes DP, Libby P, editors: Heart Disease: A Textbook of Cardiovascular
Medicine. 6th ed. Philadelphia: WB Saunders; 2001.
43. Ohmae M, Rabkin SW. Hyperkalemia-induced bundle branch block
and complete heart block. Clin Cardiol 1981;4:43-6.
44. Spodick DH. Effects of severe hyperkalemia. Am Heart Hosp
2008;6:68.
45. M a t t u A , B r a d y WJ, Pe r ro n A D. E l e c t ro c a rd i o g r a p h i c
manifestations of hypothermia. Am J Emerg Med 2000;18:
721-29.
46. Oh MS, Carroll HJ, Clemmons JE, Vagnucci AH, Levison SP, Whang ES.
A mechanism for hyporeninemic hypoaldosteronism in chronic renal
disease. Metabolism 1974;23:1157-66.
47. Chang SS, Grunder S, Hanukoglu A, Rösler A, Mathew PM, Hanukoglu
I, et al. Mutations in subunits of the epithelial sodium channel cause
salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism
type 1. Nat Genet 1996;12:248-53.
48. Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam

© JAPI  •  VOL. 56  •  SEPTEMBER 2008 www.japi.org 693